370 related articles for article (PubMed ID: 29930278)
21. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Hotta N; Kakuta H; Koh N; Fukasawa H; Yasuma T; Awaya S; Sakamoto N
Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
[TBL] [Abstract][Full Text] [Related]
22. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
23. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
24. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
25. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
27. Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.
El Gamal H; Eid AH; Munusamy S
Biomed Res Int; 2017; 2017():5903105. PubMed ID: 28386557
[TBL] [Abstract][Full Text] [Related]
28. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
29. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
30. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
31. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
32. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
33. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
34. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Uchida K; Kigoshi T; Nakano S; Ishii T; Kitazawa M; Morimoto S
Clin Ther; 1995; 17(3):460-6. PubMed ID: 7585850
[TBL] [Abstract][Full Text] [Related]
35. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
36. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
[TBL] [Abstract][Full Text] [Related]
38. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.
Finegold D; Lattimer SA; Nolle S; Bernstein M; Greene DA
Diabetes; 1983 Nov; 32(11):988-92. PubMed ID: 6416910
[TBL] [Abstract][Full Text] [Related]
39. An aldose reductase inhibitor prevents the glucose-induced increase in PDGF-beta receptor in cultured rat aortic smooth muscle cells.
Kasuya Y; Nakamura J; Hamada Y; Nakayama M; Sasaki H; Komori T; Chaya S; Watanabe G; Naruse K; Nakashima E; Kato K; Hotta N
Biochem Biophys Res Commun; 1999 Aug; 261(3):853-8. PubMed ID: 10441515
[TBL] [Abstract][Full Text] [Related]
40. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
